NCT03590054 - Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Stage III Cutaneous MelanomaStage IV Cutaneous MelanomaLocally Advanced MelanomaLocally Advanced Solid NeoplasmMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Urothelial CarcinomaNon-Small Cell Lung CarcinomaStage IB Lung Cancer AJCC v7Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Lung Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

DRUG

Abexinostat

Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle

BIOLOGICAL

Pembrolizumab

Given IV on day 1 of every 21 day cycle

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

Xynomic Pharmaceuticals, Inc.

INDUSTRY

lead

Rahul Aggarwal

OTHER